<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03647527</url>
  </required_header>
  <id_info>
    <org_study_id>PF-AROM-NPC-IMRT/TOMO</org_study_id>
    <nct_id>NCT03647527</nct_id>
  </id_info>
  <brief_title>Predictor Analysis of Acute Radiation Oral Mucositis in NPC Patients Treated With IMRT/TOMO Combined Chemotherapy</brief_title>
  <official_title>Predictive Factor Analysis of Acute Radiation Oral Mucositis in Nasopharyngeal Carcinoma Patients Treated With Precise Radiotherapy Technique Combined Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang Cancer Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Radiation induced oral mucositis which may result in reduced quality of life is commonly seen
      during radiotherapy, especially combined with chemotherapy. This study is a prospective,
      single center, and exploratory study. Two contour methods of oral mucosal will be used in
      this study. All detail information will be recorded prospectively. The aim of this study is
      to explore predictive factors of acute radiotherapy induced oral mucositis in nasopharyngeal
      carcinoma patients treated with new precise radiotherapy (intensity modulated radiotherapy or
      tomography radiotherapy) by using different dosimetric parameters and clinically relevant
      variables.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To prospectively identify the predictive value of different dosimetric parameters and assess
      the predictors of acute radiation oral mucositis in nasopharyngeal carcinoma patients treated
      with intensity modulated radiotherapy or tomography radiotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2016</start_date>
  <completion_date type="Anticipated">January 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>the highest grade of oral mucositis</measure>
    <time_frame>oral mucocitis will be checked every day during the date of initiation of radiation therapy until the date of completion of radiation therapy, the highest grade â‰¥ 3 define as severe oral mubocitis, assessed up to a month and a half</time_frame>
    <description>Radiation Therapy Oncology Group/European Organization for research and treatment acute radiation morbidity scoring criteria. Grade 0: No change over baseline, Grade 1: Injection/ may experience mild pain not requiring analgesic, Grade 2: Patchy mucositis which may produce an inflammatory serosanguinitis discharge/ may experience moderate pain requiring analgesia, Grade 3: Confluent fibrinous mucositis/ may include severe pain requiring narcotic, Grade 4: Ulceration, hemorrhage or necrosis, Grade 5: death (Higher score equals to worse outcome).</description>
  </primary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Between September 2016 and August 2018, consecutive patients with II-IVB nasopharyngeal
        carcinoma receiving intensity modulated radiotherapy or tomography radiotherapy.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1.Clinical diagnosis of nasopharyngeal carcinoma. 2.7th version American Joint Committee on
        Cancer (AJCC) stage II-IVB. 3.Age must above 18. 4.Performance status must be 0 or 1
        according to Eastern Cooperative Oncology Group.

        5.Adequate bone marrow, renal, and hepatic function.

        Exclusion Criteria:

          1. Treatment with palliative intent.

          2. Previous malignancy.

          3. Pregnancy or lactation.

          4. A history of previous radiotherapy, chemotherapy, or surgery (except diagnostic) to
             the primary tumor or nodes.

          5. Any severe coexisting disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuanyuan Chen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhejiang Cancer Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>yuanyuan chen, Professor</last_name>
      <phone>+86 13738103808</phone>
      <email>chenyy@zjcc.org.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 9, 2018</study_first_submitted>
  <study_first_submitted_qc>August 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2018</study_first_posted>
  <last_update_submitted>August 23, 2018</last_update_submitted>
  <last_update_submitted_qc>August 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhejiang Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Chen yuanyuan</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>nasopharyngeal carcinoma</keyword>
  <keyword>acute radiation oral mucositis</keyword>
  <keyword>intensity modulated radiotherapy</keyword>
  <keyword>tomography radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
    <mesh_term>Mucositis</mesh_term>
    <mesh_term>Stomatitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

